While pirfenidone, the first FDA-approved drug for idiopathic pulmonary fibrosis, blocks TGF-β expression in malignant glioma cells [33], comprehensive blockade of TGF-β might cause more severe inflammation or promote tumor formation [34,35]. This evidence concerns the gene TGFB1 and pulmonary fibrosis.